<SEC-DOCUMENT>0001104659-20-001775.txt : 20200107
<SEC-HEADER>0001104659-20-001775.hdr.sgml : 20200107
<ACCEPTANCE-DATETIME>20200107070521
ACCESSION NUMBER:		0001104659-20-001775
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200106
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200107
DATE AS OF CHANGE:		20200107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		20512076

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm201336-1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Date of Report (Date of earliest event
reported): January 6, 2020</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-12584</FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3808303</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">9605 Medical Center Drive, Suite 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Rockville, MD 20850</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; border: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 38%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01. &nbsp;&nbsp;&nbsp;Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 6, 2020, Synthetic Biologics,
Inc. (the &ldquo;Company&rdquo;) received official meeting minutes from the U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;)
following a Type C meeting held on December 2, 2019 at the Company&rsquo;s request to discuss the development of SYN-004 (ribaxamase)
in allogeneic hematopoietic cell transplant (HCT) recipients who are administered intravenous (IV) beta-lactam antibiotics in response
to fever. Based on the final meeting minutes, the Phase 1b/2a study will comprise a single center, randomized, double-blinded,
placebo-controlled clinical trial of oral SYN-004 (ribaxamase) in up to 36 evaluable adult allogeneic HCT recipients. The goal
of this study is to evaluate the safety, tolerability and potential absorption into the systemic circulation (if any) of 150 mg
oral SYN-004 (ribaxamase) administered to allogeneic HCT recipients who receive an IV beta-lactam antibiotic to treat fever. Study
participants will be enrolled into three sequential cohorts administered a different study-assigned IV beta-lactam antibiotic.
Eight participants in each cohort will receive SYN-004 (ribaxamase) and four will receive placebo. Safety and pharmacokinetic data
for each cohort will be reviewed by an independent Data and Safety Monitoring Committee, which will make a recommendation on whether
to proceed to the next IV beta-lactam antibiotic. The study will also evaluate potential protective effects of SYN-004 (ribaxamase)
on the gut microbiome as well as generate preliminary information on potential therapeutic benefits and patient outcomes of SYN-004
(ribaxamase) in allogeneic HCT recipients. Enrollment is expected to begin during the first quarter of 2020 contingent upon approval
of the clinical study protocol by the Washington University School of Medicine&rsquo;s Institutional Review Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The press release attached as Exhibit 99.1
to this Current Report on Form 8-K, which is incorporated herein by reference, includes &ldquo;safe harbor&rdquo; language pursuant
to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide
presentation are &ldquo;forward-looking&rdquo; rather than historical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company undertakes no duty or obligation
to update or revise information included in this Current Report on Form 8-K or the press release attached as Exhibit 99.1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. &nbsp;&nbsp;&nbsp;Financial Statements and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 3%">&nbsp;</TD>
    <TD STYLE="width: 91%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid">Exhibit<BR>
        No.</P></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid">Description</P></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt"><A HREF="tm201336-1_ex991.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="tm201336-1_ex991.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release issued by Synthetic Biologics, Inc. dated January 7, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: January 7, 2020</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Steven A. Shallcross</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title: &nbsp;&nbsp;Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 13%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B><BR>
<B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 85%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tm201336-1_ex991.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1&nbsp;</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tm201336-1_ex991.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release issued by Synthetic Biologics, Inc. dated January 7, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm201336-1_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Receives FDA Guidance
at Type C Meeting for SYN-004 (ribaxamase) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Phase 1b/2a Clinical Trial in Allogeneic
HCT Recipients</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rockville, MD, January 7, 2020 &ndash;
</B><U>Synthetic Biologics, Inc.</U> (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop
therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced the receipt
of official meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type C meeting held on December 2, 2019
at the Company&rsquo;s request to discuss the development of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant
(HCT) recipients who are administered intravenous (IV) beta-lactam antibiotics in response to fever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Our discussion with the FDA was
extremely productive and reinforces our optimism in the potential of SYN-004 (ribaxamase) to prevent dysbiosis of the gut microbiome
and significantly improve outcomes for patients who undergo allogeneic HCT and are treated with IV beta-lactam antibiotics,&rdquo;
said Steven A. Shallcross, Chief Executive and Financial Officer of Synthetic Biologics. &ldquo;We remain focused on working with
the distinguished team at the Washington University School of Medicine in St. Louis to finalize the clinical program protocol in
anticipation of the commencement of the Phase 1b/2a clinical study during the first quarter of 2020.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the final meeting minutes, the
Phase 1b/2a study will comprise a single center, randomized, double-blinded, placebo-controlled clinical trial of oral SYN-004
(ribaxamase) in up to 36 evaluable adult allogeneic HCT recipients. The goal of this study is to evaluate the safety, tolerability
and potential absorption into the systemic circulation (if any) of 150 mg oral SYN-004 (ribaxamase) administered to allogeneic
HCT recipients who receive an IV beta-lactam antibiotic to treat fever. Study participants will be enrolled into three sequential
cohorts administered a different study-assigned IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN-004
(ribaxamase) and four will receive placebo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Safety and pharmacokinetic data for each
cohort will be reviewed by an independent Data and Safety Monitoring Committee, which will make a recommendation on whether to
proceed to the next IV beta-lactam antibiotic. The study will also evaluate potential protective effects of SYN-004 (ribaxamase)
on the gut microbiome as well as generate preliminary information on potential therapeutic benefits and patient outcomes of SYN-004
(ribaxamase) in allogeneic HCT recipients. Enrollment is expected to begin during the first quarter of 2020 contingent upon approval
of the clinical study protocol by the Washington University School of Medicine&rsquo;s Institutional Review Board (IRB).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About SYN-004 (ribaxamase)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SYN-004 (ribaxamase) is an oral prophylactic
therapy designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut
microbiome for the prevention of <I>Clostridioides difficile</I> infection (CDI), overgrowth of pathogenic organisms, the emergence
of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT)
recipients. Allogeneic HCT recipients routinely receive long courses of IV beta-lactam antibiotics to treat infection. Antibiotic-mediated
damage of the gut microbiome in allogeneic HCT recipients has been strongly associated with adverse outcomes including CDI, vancomycin-resistant
enterococci (VRE) colonization and potentially fatal bacteremia and aGVHD. A previously completed placebo-controlled Phase 2b clinical
trial of 412 patients demonstrated SYN-004 (ribaxamase) protected the gut microbiome from antibiotic-mediated dysbiosis. Patients
receiving SYN-004 (ribaxamase) also demonstrated significantly better maintenance and recovery of the gut microbiome as well as
lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American:
SYN) is a clinical-stage company developing therapeutics that preserve the microbiome to protect and restore the health of patients.
The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV)
beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, <I>C. difficile</I> infection (CDI),
overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD)
in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010, which is intended to reduce the impact of methane-producing
organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company
is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and
systemic diseases, and has completed proof-of-concept studies with monoclonal antibody therapies for the prevention and treatment
of pertussis. For more information, please visit Synthetic Biologics' website at <U>www.syntheticbiologics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements
can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot;
 &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions,
and includes statements regarding potential protective effects of SYN-004 (ribaxamase) on the gut microbiome as well as generate
preliminary information on potential therapeutic benefits and patient outcomes of SYN-004 (ribaxamase) in allogeneic HCT recipients,
enrollment expected to begin during the first quarter of 2020 contingent upon approval of the clinical study protocol by the Washington
University School of Medicine&rsquo;s Institutional Review Board (IRB) and the intended benefits to be derived from SYN-004, SYN-010
and SYN-020. These forward-looking statements are based on management's expectations and assumptions as of the date of this press
release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual
results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ materially from current expectations include, among others, Synthetic
Biologics' ability to continue to comply with continued listing requirements of the NYSE American, the ability of its product candidates
to demonstrate safety and effectiveness, as well as results that are consistent with prior results, Synthetic Biologics' clinical
trials continuing and/or beginning enrollment as expected, a failure to receive the necessary regulatory approvals for commencement
of clinical trials and commercialization of Synthetic Biologics' therapeutics, including approval of proposed trial designs, a
failure of Synthetic Biologics' clinical trials, and those conducted by investigators, for SYN-004 and SYN-010 to be commenced
or completed on time or to achieve desired results and benefits, a failure of Synthetic Biologics' clinical trials to continue
enrollment as expected or receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market or sell
its products, Synthetic Biologics' inability to maintain its material licensing agreements, or a failure by Synthetic Biologics
or its strategic partners to successfully commercialize products, Synthetic Biologics&rsquo; ability to achieve acceptance of its
product candidates in the marketplace and the successful development, marketing or sale of Synthetic Biologics' products by competitors
that render Synthetic Biologics' products obsolete or non-competitive, the continued maintenance and growth of Synthetic Biologics'
patent estate, Synthetic Biologics becoming and remaining profitable, Synthetic Biologics' ability to obtain or maintain the capital
or grants necessary to fund its research and development activities, a loss of any of Synthetic Biologics' key scientists or management
personnel and other factors described in Synthetic Biologics' Form 10-K and 10-K/A for the year ended December 31, 2018 and its
other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided
only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future events, or otherwise, except as required by law.</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director, Corporate Communication, (240)
660-2000, <U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@ogilvy.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 1T# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
